S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VRNA

Verona Pharma (VRNA) Stock Price, News & Analysis

$16.09
-0.41 (-2.48%)
(As of 03/28/2024 ET)
Today's Range
$15.80
$16.73
50-Day Range
$15.30
$19.07
52-Week Range
$11.83
$23.81
Volume
309,348 shs
Average Volume
515,525 shs
Market Capitalization
$1.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00

Verona Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.1% Upside
$33.00 Price Target
Short Interest
Bearish
8.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.42mentions of Verona Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.23) to ($0.61) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

690th out of 938 stocks

Pharmaceutical Preparations Industry

312th out of 425 stocks

VRNA stock logo

About Verona Pharma Stock (NASDAQ:VRNA)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Stock Price History

VRNA Stock News Headlines

VRNA Apr 2024 17.500 call
VRNA Apr 2024 15.000 call
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Andrew Fisher Joins Verona Pharma as General Counsel
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Verona Pharma earnings preview: what to expect
When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?
Verona Pharma PLC ADR
VRNA Mar 2024 15.000 put
VRNA Jun 2024 30.000 call
Verona Pharma: A Few Points From The Bull And Bear Case
Verona Pharma PLC ADR (VRNA)
Piper Sandler Reaffirms Their Buy Rating on Verona Pharma (VRNA)
Verona Pharma Secures Debt Facility Of Up To $400 Mln
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$35.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+100.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-54,370,000.00
Pretax Margin
-10,946.07%

Debt

Sales & Book Value

Annual Sales
$460,000.00
Book Value
$3.12 per share

Miscellaneous

Free Float
76,103,000
Market Cap
$1.32 billion
Optionable
Optionable
Beta
0.42
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives


VRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price target for 2024?

3 brokerages have issued 12 month price objectives for Verona Pharma's stock. Their VRNA share price targets range from $32.00 to $35.00. On average, they expect the company's share price to reach $33.00 in the next year. This suggests a possible upside of 105.1% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2024?

Verona Pharma's stock was trading at $19.88 at the beginning of the year. Since then, VRNA stock has decreased by 19.1% and is now trading at $16.09.
View the best growth stocks for 2024 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Thursday, February, 29th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07.

What ETF holds Verona Pharma's stock?

ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

Verona Pharma (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (4.84%), Wellington Management Group LLP (4.73%), Jennison Associates LLC (1.98%), Eventide Asset Management LLC (1.72%), First Turn Management LLC (1.51%) and Bellevue Group AG (1.05%). Insiders that own company stock include Anders Ullman, Claire Poll, David R Ebsworth, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Martin Edwards, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends
.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRNA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners